Apple has just made final macOS Sierra 10.12 download available to all after months of developer and public testing, meaning that compatible Mac owners can get their hands on it right now. Apple officially introduced macOS Sierra to the world back in June as part of the opening keynote of this year’s Worldwide Developers Conference. Or, if there's anyone you trust well enough, you could even change your Apple ID password temporarily, and have a friend log in on their computer to 'purchase' Keynote for you. I'm quite sure the Sierra installer does not come with Keynote. But, if it did, you'd be able to extract Keynote via Pacifist. My 'non-touchbar' 15 inch MacBook Pro with Keynote 7.2 using macOS 10.12.6 allows me to group selected shapes, a shape and an image and a shape with a text box. Probably of little assistance but at least we have eliminated some of the 'variables'. 3475-B98 2020-005628-12 ( EudraCT Number ) MK-3475-B98 ( Other Identifier: Merck ) KEYNOTE-B98 ( Other Identifier: Merck ) First Posted: June 24, 2021 Key Record Dates: Last Update Posted: August 6, 2021 Last Verified: August 2021 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: Yes.
Go toThis study is a rolling arm study of pembrolizumab in combination with investigational agents in participants with anti-programmed cell death 1 (PD-1)/ programmed cell death ligand 1 (PD-L1) refractory ES-SCLC in need of second-line treatment. This study will have 2 parts: an initial safety lead-in to determine safety and tolerability for experimental combinations of investigational agents without an established recommended phase 2 dose (RP2D) followed by an efficacy evaluation.
Investigational agents will initiate directly in or be added to the efficacy evaluation after an initial evaluation of safety and tolerability of the investigational agent has been completed in a separate study or in the safety lead-in of this study. If an RP2D for a combination being evaluated in the safety lead-in is established from another study, then the efficacy evaluation may begin at the determined RP2D.
There will be no hypothesis testing in this study.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Small Cell Lung Carcinoma | Biological: coformulation pembrolizumab/quavonlimabDrug: lenvatinibBiological: MK-4830Biological: coformulation favezelimab/pembrolizumab | Phase 1Phase 2 |
Go to
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 80 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Investigational Agents for the Treatment of Participants With PD-1/L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy (KEYNOTE-B98) |
| Estimated Study Start Date : | August 6, 2021 |
| Estimated Primary Completion Date : | November 2, 2026 |
| Estimated Study Completion Date : | November 2, 2026 |
Resource links provided by the National Library of MedicineKeynote 10.12 6 Download
Go to
This study is a rolling arm study of pembrolizumab in combination with investigational agents in participants with anti-programmed cell death 1 (PD-1)/ programmed cell death ligand 1 (PD-L1) refractory ES-SCLC in need of second-line treatment. This study will have 2 parts: an initial safety lead-in to determine safety and tolerability for experimental combinations of investigational agents without an established recommended phase 2 dose (RP2D) followed by an efficacy evaluation.
Investigational agents will initiate directly in or be added to the efficacy evaluation after an initial evaluation of safety and tolerability of the investigational agent has been completed in a separate study or in the safety lead-in of this study. If an RP2D for a combination being evaluated in the safety lead-in is established from another study, then the efficacy evaluation may begin at the determined RP2D.
There will be no hypothesis testing in this study.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Small Cell Lung Carcinoma | Biological: coformulation pembrolizumab/quavonlimabDrug: lenvatinibBiological: MK-4830Biological: coformulation favezelimab/pembrolizumab | Phase 1Phase 2 |
Go to
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 80 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Investigational Agents for the Treatment of Participants With PD-1/L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy (KEYNOTE-B98) |
| Estimated Study Start Date : | August 6, 2021 |
| Estimated Primary Completion Date : | November 2, 2026 |
| Estimated Study Completion Date : | November 2, 2026 |